Complications of radioactive iodine treatment of thyroid carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 11, 2010, Pages 1277-1287

  Lee, Stephanie L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Radioactive iodine; Radioiodine; Second primary malignancy; Sialoadenitis; Thyroid carcinoma

Indexed keywords

ALUMINUM HYDROXIDE; AMIFOSTINE; CEVIMELINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; FLUORIDE; IODINE 123; IODINE 124; IODINE 131; LIDOCAINE; MAGNESIUM HYDROXIDE; MOUTHWASH; ONDANSETRON; PILOCARPINE; RECOMBINANT THYROTROPIN; TECHNETIUM 99M;

ACUPUNCTURE; ACUTE TOXICITY; AGEUSIA; AMENORRHEA; ANEMIA; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANDIDIASIS; CHRONIC TOXICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGENITAL MALFORMATION; CORTICOSTEROID THERAPY; DACRYOCYSTORHINOSTOMY; DENTAL CARE; DENTAL CARIES; DRUG MECHANISM; DRUG MEGADOSE; DRUG UPTAKE; ECHOGRAPHY; ENDOSCOPY; EPIPHORA; HUMAN; HYDRATION; LACRIMAL DUCT OCCLUSION; LEMON JUICE; LOW DRUG DOSE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MALE INFERTILITY; MASSAGE; METASTASIS; MOUTH PAIN; MOUTH ULCER; NAUSEA; NAUSEA AND VOMITING; NECK PAIN; NEUTROPENIA; OLIGOMENORRHEA; PAROTID GLAND; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION SICKNESS; REVIEW; RHINITIS; SALIVARY DUCT OBSTRUCTION; SALIVARY GLAND DISEASE; SALIVARY GLAND PAIN; SECOND CANCER; SIALOADENITIS; SIALOENDOSCOPY; SIALOGRAPHY; SIDE EFFECT; STENT; STOMATITIS; SWEATING; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROIDECTOMY; THYROIDITIS; TREATMENT CONTRAINDICATION; URINARY FREQUENCY; VOMITING; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

EID: 78951486728     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0094     Document Type: Review

References (77)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
2. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006;94:692-700.
3. Verburg FA, Dietlein M, Lassmann M, et al. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:343-346.
4. Alexander C, Bader JB, Schaefer A, et al. Intermediate and longterm side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.
5. Mendoza A, Shaffer B, Karakla D, et al. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 2004;14:133-140.
6. L'Annunziata M. Nuclear radiation, its interaction with matter and radioactive decay. In: L'Annunziata M, ed. Handbook of Radioactivity Analysis, 2nd ed. San Diego, CA: Academic Press; 2003:19.
7. Snyder W, Ford M, Warner GG, et al. "S", absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. Reston, VA: Society of Nuclear Medicine; 1975.
8. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.
9. Spiegel W, Reiners C, Borner W. Sialoadenitis following iodine-I131 therapy for thyroid carcinoma [letter]. J Nucl Med 1985;26:816.
10. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996;35:535-540.
11. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med 1984;25:755-758.
12. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002;27:767-771.
13. Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009;50:1605-1610.
14. Taieb D, Sebag F, Farman-Ara B, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropinassisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 2010;95:3283-3290.
15. Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-1782.
16. Van Nostrand D, Atkins F, Bandaru VV, et al. Salivary gland protection with sialagogues: a case study. Thyroid 2009;19:1005-1008.
17. Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124)I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 2010; in press.
18. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46:261-266.
19. Bohuslavizki KH, Klutmann S, Bleckmann C, et al. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. Strahlenther Onkol 1999;175:57-61.
20. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999;175(Suppl 4):6-12.
21. Kim SJ, Choi HY, Kim IJ, et al. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 2008;18:325-331.
22. Ma C, Xie J, Jiang Z, et al. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:1778-1785.
23. Capaccio P, Cuccarini V, Ottaviani F, et al. Comparative ultrasonographic, magnetic resonance sialographic, and videoendoscopic assessment of salivary duct disorders. Ann Otol Rhinol Laryngol 2008;117:245-252.
24. Mandel L, Liu F. Salivary gland injury resulting from exposure to radioactive iodine: case reports. J Am Dent Assoc 2007;138:1582-1587.
25. Bomeli SR, Schaitkin B, Carrau RL, Walvekar RR. Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope 2009;119:864-867.
26. Kim JW, Han GS, Lee SH, et al. Sialoendoscopic treatment for radioiodine induced sialadenitis. Laryngoscope 2007;117:133-136.
27. Nahlieli O, Abramson A, Shacham R, et al. Endoscopic treatment of salivary gland injuries due to facial rejuvenation procedures. Laryngoscope 2008;118:763-767.
28. Nahlieli O, Neder A, Baruchin AM. Salivary gland endoscopy: a new technique for diagnosis and treatment of sialolithiasis. J Oral Maxillofac Surg 1994;52:1240-1242.
29. Napenas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology 2009;97:76-83.
30. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010;18:1061-1079.
31. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-460.
32. Jedel E. Acupuncture in xerostomia - a systematic review. J Oral Rehabil 2005;32:392-396.
33. Blom M, Dawidson I, Fernberg JO, et al. Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B:182-190.
34. Johnstone PA, Peng YP, May BC, et al. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-357.
35. Shiboski CH, Hodgson TA, Ship JA, Schiodt M. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl):S66.e1-19.
36. Kita T, Yokoyama K, Higuchi T, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 2004;18:345-349.
37. Maenpaa HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One 2008;3:e1885.
38. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986;27:1519-1527.
39. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 2010;17:R161-172.
40. Van Nostrand D, Freitas J. Side effects of I-131 for ablation and treatment of well-differentiated thyroid carcinoma. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press; 2006:459-484.
41. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87:5817-5820.
42. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg 2004;20:126-129.
43. Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg 2005;21:337-344.
44. Burnstine MA. New lacrimal cannula for probing and irrigation in the tearing patient. Arch Ophthalmol 2007;125:419.
45. Hyer S, Vini L, O'Connell M, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002;56:755-758.
46. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35:1418-1422. (Pubitemid 24280445)
47. Garsi JP, Schlumberger M, Ricard M, et al. Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clin Endocrinol (Oxf), in press.
48. Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 2008;68:610-617.
49. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989;69:186-190.
50. Souza Rosario PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes 2005;113:331-333.
51. Vini L, Hyer S, Al-Saadi A, et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002;78:92-93.
52. Smith MB, Xue H, Takahashi H, et al. Iodine 131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects. Ann Surg Oncol 1994;1:128-131.
53. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976;17:460-464.
54. Bal C, Kumar A, Tripathi M, et al. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int J Radiat Oncol Biol Phys 2005;63:449-455.
55. Ceccarelli C, Canale D, Vitti P. Radioactive iodine (131I) effects on male fertility. Curr Opin Urol 2008;18:598-601.
56. Garsi JP, Schlumberger M, Rubino C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 2008;49:845-852.
57. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996;37:606-612.
58. Sisson JC, Carey JE. Thyroid carcinoma with high levels of function: treatment with (131)I. J Nucl Med 2001;42:975-983.
59. Molinaro E, Leboeuf R, Shue B, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid 2009;19:1035-1041.
60. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-182.
61. Leeper RD. Thyroid Cancer. Med Clin North Am 1985;69:1079-1096.
62. Haynie TP, Beierwaltes WH. Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med 1963;4:85-91.
63. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-1591.
64. Leeper RD, Shimaoka K. Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 1980;9:383-404.
65. Lee J, Sogutlu G, Leard L, et al. Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma. Thyroid 2007;17:367-369.
66. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-1644.
67. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-515.
68. Berthe E, Henry-Amar M, Michels JJ, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31:685-691.
69. Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 2006;115:607-610.
70. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005;117:281-288.
71. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007;17:1277-1288.
72. Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev 2008;17:1543-1549.
73. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19:451-457.
74. Rubino C, Adjadj E, Doyon F, et al. Radiation exposure and familial aggregation of cancers as risk factors for colorectal cancer after radioiodine treatment for thyroid carcinoma. Int J Radiat Oncol Biol Phys 2005;62:1084-1089.
75. Schneider AB, Viana MA, Ron E. Weighing shadows: can metaanalysis help define the risk-benefit ratio of RAI treatment for lowrisk thyroid cancer patients? Thyroid 2009;19:435-436.
76. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
77. Kloos RT. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid 2009;19:925-928.